Overview

A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

Status:
Not yet recruiting
Trial end date:
2024-05-23
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atopic dermatitis (AD) and skin of color.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company